Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk is shifting its business model toward high volume at lower net prices as demand for GLP-1 medicines compounds. The pharmaceutical company is defending its position with the Wegovy pill and higher-dose Wegovy. This commercial pivot follows prior strategic acquisitions aimed at improving diabetes and obesity treatments, including a deal to buy Emisphere Technologies for $1.8 billion to develop oral medicines. Novo Nordisk also previously secured an agreement with Nanexa utilizing the PharmaShell platform for long-acting peptide treatments.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novo Nordisk previously agreed to buy Emisphere Technologies for $1.8 billion to develop oral diabetes medicines.
- ✓ Novo Nordisk previously reached an agreement with Nanexa for the PharmaShell platform to create long-acting peptide medicines.
- ✓ Demand for GLP-1 medicines is still compounding.
- ✓ Eli Lilly is capturing most of the growth in the GLP-1 market.
What changed
Novo Nordisk is defending its market position with the Wegovy pill and higher-dose Wegovy as demand for GLP-1 medicines shifts from high list prices to high volume at lower net prices.
Live updates
-
Novo Nordisk Invests in Drug Delivery Tech Amid Shift in GLP-1 Market
Novo Nordisk is shifting its business model toward high volume at lower net prices as demand for GLP-1 medicines compounds. The pharmaceutical company is defending its position with the Wegovy pill and higher-dose Wegovy. This commercial pivot follows prior strategic acquisitions aimed at improving diabetes and obesity treatments, including a deal to buy Emisphere Technologies for $1.8 billion to develop oral medicines. Novo Nordisk also previously secured an agreement with Nanexa utilizing the PharmaShell platform for long-acting peptide treatments.
Why it matters
The pharmaceutical sector is adapting to intense market pressures by altering how treatments are priced and delivered. Novo Nordisk relies on oral and long-acting dosing innovations to maintain competitiveness against rivals like Eli Lilly, which currently captures a larger share of market growth. Financial tracking requires evaluating company-reported growth rates and margins rather than absolute amounts due to differing currency reporting.
What is confirmed
- Novo Nordisk previously agreed to buy Emisphere Technologies for $1.8 billion to develop oral diabetes medicines.
- Novo Nordisk previously reached an agreement with Nanexa for the PharmaShell platform to create long-acting peptide medicines.
- Demand for GLP-1 medicines is still compounding.
- Eli Lilly is capturing most of the growth in the GLP-1 market.
What to watch next
- Commercial performance and volume growth of the Wegovy pill and higher-dose Wegovy.
- Comparative growth rates and margins reported by Novo Nordisk and Eli Lilly.
confidence 100%Sources used for this update (3)
- www.novonordisk.com — Press releases - Novo Nordisk
- www.onedayadvisor.com — GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills ...
- www.distillintelligence.com — Latest Nanexa News & Announcements | Distill
-
Novo Nordisk to Acquire Emisphere for $1.8 Billion
Novo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion to develop oral diabetes medicines. This deal follows a separate agreement with Nanexa for the PharmaShell platform to create long-acting peptide medicines. Both investments signal a strategic shift toward oral administration and long-acting dosing for obesity and type 2 diabetes treatments.
Why it matters
Novo Nordisk is making significant investments to maintain market dominance in obesity and type 2 diabetes treatments. The company's deals with Emisphere, Nanexa, and Orbis Medicines reflect its focus on oral administration and long-acting dosing. This strategic shift aims to counter competitors and expand treatment options.
What is confirmed
- Novo Nordisk agreed to buy Emisphere Technologies for $1.8 billion.
What to watch next
- Completion of the Emisphere acquisition
- Progress on oral cardiometabolic therapies with Orbis Medicines
- Development of long-acting peptide medicines with Nanexa's PharmaShell platform
confidence 100%Sources used for this update (2)
- pharmaphorum.com — Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bn
- uk.marketscreener.com — Nanexa AB Share Price (NANEXA) - Stock Nasdaq Stockholm ...
-
Novo Nordisk expands cardiometabolic portfolio with Orbis Medicines deal
Novo Nordisk signed a deal worth up to $1.4 billion with Copenhagen-based Orbis Medicines to develop oral cardiometabolic therapies. This agreement follows a separate deal with Nanexa for the PharmaShell platform to create long-acting peptide medicines. Together, these investments signal a strategic shift toward oral administration and long-acting dosing for obesity and type 2 diabetes treatments to maintain market dominance against competitors.
Why it matters
The company is transitioning its GLP-1 based injectable business into a pill-based model. This occurs as larger pharmaceutical firms seek biology and dosing methods that complement existing weight-loss medicines.
What is confirmed
- Novo Nordisk signed a deal worth up to $1.4 billion with Orbis Medicines for oral cardiometabolic therapies.
- Novo Nordisk entered a collaboration with Nanexa worth up to 1.165 billion euros or approximately $1.3 billion.
Still unconfirmed
- Novo Nordisk is attempting to turn its injectable GLP-1 empire into a pill business before competitors do.
- Palatin may fit the pattern of recent obesity-related acquisitions and licensing deals.
What to watch next
- Clinical trial data for Orbis Medicines oral therapies
- Progress on the five long-acting peptide programs with Nanexa
confidence 90%Sources used for this update (3)
- biotechmorning.com — Novo Nordisk's $1.4 Billion Bet That Pills Can Replace Needles
- www.investegate.co.uk — Big Pharma's Obesity Shopping Spree Is Moving...
- www.newsdirect.com — Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s ...
-
Novo Nordisk Shares Face Pressure Despite Nanexa Deal
Novo Nordisk shares remain under pressure as investors weigh obesity and diabetes data against competitive concerns and cautious analyst sentiment. This follows a global exclusive license and collaboration agreement with Swedish biotech Nanexa worth up to 1.165 billion euros or approximately $1.3 billion. The transaction grants Novo exclusive rights to the PharmaShell atomic layer deposition platform to develop long-acting peptide medicines targeting obesity, type 2 diabetes, and other cardiometabolic diseases. The partnership covers up to five long-acting peptide programs.
Why it matters
The collaboration highlights the growing significance of advanced drug-delivery systems in extending therapy durations for patients. Market observers continue to monitor Novo Nordisk amid broader investor scrutiny regarding growth outlooks and competitor positioning. Additional tracking of business development and licensing deals highlights ongoing activity across the biopharma sector.
What is confirmed
- Novo Nordisk shares remain under pressure as investors weigh obesity and diabetes data against competitive concerns and cautious analyst sentiment.
- Novo Nordisk secured a global exclusive license and collaboration agreement with Nanexa worth up to 1.165 billion euros or approximately $1.3 billion.
Still unconfirmed
- Concerns over the company growth outlook are actively depressing stock performance.
What to watch next
- Updates on the five long-acting peptide programs developed via the PharmaShell platform.
- Further market reaction to Novo Nordisk obesity and diabetes data.
confidence 85%Sources used for this update (4)
- www.marketbeat.com — NVO News Today | Why did Novo Nordisk A/S stock go down today?
- www.biobucks.co — Biotech BD&L Tracker 2026: 156 Licensing & Partnering Deals
- www.marketscreener.com — Latest news about Nanexa AB - MarketScreener
- de.marketscreener.com — Nanexa AB Aktie (A2JA78) - Kurs Nasdaq Stockholm ...
-
Novo Nordisk Agrees to $1.3 Billion Deal for Nanexa Tech
Novo Nordisk has secured a global exclusive license and collaboration agreement with Swedish biotech Nanexa worth up to 1.165 billion euros or approximately $1.3 billion. The transaction grants Novo exclusive rights to the PharmaShell atomic layer deposition platform to develop long-acting peptide medicines targeting obesity, type 2 diabetes, and other cardiometabolic diseases. The partnership covers up to five long-acting peptide programs, highlighting the growing significance of advanced drug-delivery systems in extending therapy durations for patients.
Why it matters
Drug delivery platforms like PharmaShell aim to convert existing treatments into longer-acting options, such as once-quarterly injectables. The agreement forms part of a broader corporate push by the Danish drugmaker, which faces strong market competition from Eli Lilly. CFRA recently cut the stock to Sell, while the FDA review of Denecimig stays open.
What is confirmed
- Novo Nordisk signed a global exclusive license and collaboration agreement with Nanexa worth up to 1.165 billion euros or approximately $1.3 billion.
- The deal gives Novo exclusive rights to the PharmaShell atomic layer deposition platform for up to five long-acting peptide programmes.
- The collaboration targets the development of long-acting peptide medicines for patients treating obesity, type 2 diabetes, and other cardiometabolic diseases.
Still unconfirmed
- CFRA cut the stock to Sell while an FDA review of Denecimig stays open and Novo Nordisk cuts 108 US jobs.
What to watch next
- Progress updates on the five long-acting peptide programmes utilizing the PharmaShell platform
- Regulatory decisions regarding Denecimig and the status of ongoing FDA reviews
confidence 100%Sources used for this update (4)
- www.europesays.com — Novo Nordisk Bets $1.3 Billion on Longer-Acting Drug Delivery ...
- biotechresearch.co.uk — Novo Nordisk / Nanexa PharmaShell Deal: Long-Acting Peptide ...
- www.ad-hoc-news.de — Novo Nordisk Licenses Two Drug Candidates While Cutting 108 ...
- www.cnbc.com — Novo Nordisk rebrands to 'Novo' under CEO Mike Doustdar - CNBC
-
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Novo Nordisk has signed a global exclusive license and collaboration agreement with Swedish biotech Nanexa worth up to 1.165 billion euros or approximately $1.3 billion. The deal grants Novo exclusive rights to the PharmaShell atomic layer deposition platform to develop long-acting peptide medicines for patients treating obesity, type 2 diabetes, and other cardiometabolic diseases.
Why it matters
This deal is significant as it allows Novo Nordisk to expand its portfolio of treatments for chronic diseases. The PharmaShell technology has the potential to enable monthly and quarterly injections, providing patients with more convenient treatment options. Novo Nordisk is a leading pharmaceutical company with a long history of innovation in diabetes and obesity care.
What is confirmed
- Novo Nordisk agreed to pay up to $1.3 billion to license and develop Nanexa's drug delivery technology.
- The deal grants Novo exclusive rights to the PharmaShell atomic layer deposition platform.
- Novo Nordisk intends to use this technology to create monthly and quarterly injections for patients treating obesity, type 2 diabetes, and other cardiometabolic diseases.
What to watch next
- Progress in developing long-acting peptide medicines using the PharmaShell technology
- Regulatory approvals for the new treatments
- Commercialization and market launch of the new treatments
confidence 100%Sources used for this update (8)
- www.novonordisk.com — Novo Nordisk
- www.europesays.com — Novo Nordisk Licenses Nanexa Tech in Deal Valued Up to $1.3 ...
- app.novo.co — Novo | Login
- www.novobp.com — Novo Building Products
- www.novonordisk-us.com — Welcome to Novo in the U.S. | Novo U.S. Website
- www.novo.co — Novo: Free Business Bank Account for Small Businesses | Novo
- www.novo.co — Free Business Checking Account, No Monthly Fees | Novo | Novo
- en.wikipedia.org — Novo (company) - Wikipedia
-
Novo Nordisk Secures Exclusive License for Nanexa PharmaShell Technology
Novo Nordisk signed a global exclusive license and collaboration agreement with Swedish biotech Nanexa worth up to 1.165 billion euros, or approximately 1.3 billion dollars. The deal grants Novo exclusive rights to the PharmaShell atomic layer deposition platform to develop long-acting peptide medicines. The company intends to use this technology to create monthly and quarterly injections for patients treating obesity, type 2 diabetes, and other cardiometabolic diseases. Nanexa shares more than doubled in early trading on Friday following the announcement, which occurred after markets closed on Thursday.
Why it matters
Novo Nordisk aims to launch over five multi-blockbuster drugs by 2030. Reducing dosing frequency for GLP-1 treatments is a primary research and development focus to strengthen its position in the cardiometabolic market.
What is confirmed
- Novo Nordisk signed a global exclusive license and collaboration agreement with Nanexa worth up to 1.165 billion euros.
- The deal provides Novo Nordisk exclusive rights to the PharmaShell long-acting injectable drug delivery platform.
- The partnership targets the development of monthly and quarterly injections for obesity and type 2 diabetes.
- Nanexa shares more than doubled in value during early Friday trading.
- The agreement covers long-acting injectable drugs for obesity, type 2 diabetes, and other cardiometabolic diseases.
What to watch next
- Clinical trial results for PharmaShell-based monthly or quarterly injections
- Updates on Novo Nordisk's progress toward its 2030 goal of five multi-blockbusters
confidence 100%Sources used for this update (15)
- www.fiercebiotech.com — Novo inks $1.3B Nanexa deal to unlock long-acting obesity ...
- finance.yahoo.com — Novo Nordisk signs $1.3 billion deal for long-acting obesity ...
- www.gurufocus.com — Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
- live.euronext.com — Nanexa shares soar on €1.17 billion Novo Nordisk deal for ...
- finance.yahoo.com — Novo inks $1.33bn long-lasting injectable pact with Sweden ...
- www.nextmsc.com — Novo Nordisk-Nanexa €1.17B Drug Delivery Devices Deal
- www.nordiskpost.com — Novo signs €1.17 billion deal for Swedish injection technology
- www.drugdeliverybusiness.com — Novo taps Nanexa for long-acting injectables with €1.17B pact
- www.manufacturingchemist.com — Nanexa signs €1.165bn Novo deal for long-acting injectable ...
- www.healthcaremea.com — Novo Nordisk inks US$1.3B licensing agreement with Sweden's ...
- www.rttnews.com — Novo Nordisk Licenses Nanexa's PharmaShell In Deal Worth Up ...
- www.fool.com — Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's ...
-
Novo Nordisk Agrees to $1.3B Deal for Nanexa Tech
Swedish drug-delivery firm Nanexa saw its shares surge following a global licensing and collaboration agreement with Novo Nordisk worth up to €1.165 billion, or approximately $1.3 billion. The partnership centers on injection technology designed to make diabetes and obesity treatments longer-lasting, enabling the Wegovy maker to pursue extended-release drug options. Trading activity pushed the microcap stock sharply higher in early Friday market sessions as investors responded to the multimillion-dollar biotechnology deal.
Why it matters
The collaboration gives the European pharmaceutical giant access to specialized delivery systems that could improve patient adherence by reducing injection frequency for chronic conditions. Microcap companies partnering with major industry players often experience extreme market volatility upon public disclosure of such agreements. This particular arrangement targets the lucrative and rapidly expanding market for weight-loss therapeutics.
What is confirmed
- Novo Nordisk agreed to a global licensing and collaboration agreement with Nanexa worth up to €1.165 billion or $1.3 billion.
- The partnership covers injection technology aimed at making obesity and diabetes treatments longer-lasting.
- Nanexa shares surged significantly in early Friday trading following the announcement.
What to watch next
- Further clinical or development milestones resulting from the collaboration between Novo Nordisk and Nanexa
- Subsequent stock performance and trading volume for Nanexa
confidence 100%Sources used for this update (3)
- finance.yahoo.com — Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
- finance.yahoo.com — Nanexa shares rocket 114% on $1.3 billion Novo Nordisk ...
- www.cnbc.com — Pharma stock soars 150% on injectables deal with Wegovy maker ...
-
Novo Nordisk to Pay Up to $1.3B for Nanexa Technology
Wegovy maker Novo Nordisk has agreed to pay up to $1.3 billion for Nanexa drug delivery technology, prompting a major surge in Nanexa shares. The agreement involves injection technology worth €1.17 billion, allowing Novo Nordisk to pursue long-acting obesity drugs. The multi-million-dollar deal unlocks long-acting obesity injectables for the pharmaceutical company, driving a significant 150 percent surge in the pharmaceutical stock on the market following the announcement of the injectables partnership.
Why it matters
The acquisition targets advanced drug delivery technology to support long-acting treatments for obesity. Novo Nordisk continues to expand its pipeline for weight management products through external partnerships. Financial terms place the ceiling of the agreement near $1.3 billion or €1.17 billion.
What is confirmed
- Novo Nordisk is paying up to $1.3 billion for Nanexa’s drug delivery technology.
- The transaction value is noted at €1.17 billion in connection with the injection technology deal.
- Nanexa shares soared following the announcement of the injectables deal with the Wegovy maker.
- The agreement is aimed at unlocking long-acting obesity injectables.
What to watch next
- Further announcements regarding the clinical development timelines for long-acting obesity injectables using Nanexa's technology.
- Regulatory filings or financial disclosures detailing the milestone payment schedule of the $1.3 billion deal.
confidence 100%Sources used for this update (5)
- WSJ — Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
- CNBC — Pharma stock soars 150% on injectables deal with Wegovy maker Novo
- reuters.com — Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
- finance.yahoo.com — Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
- Fierce Biotech — Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community